Xenon Pharmaceuticals sees XEN1101 Phase 1 trial completed by mid-year
Xenon Pharmaceuticals provided a corporate update and outlined its anticipated key corporate milestones for 2018. Dr. Simon Pimstone, Xenon's President and CEO, said, "Xenon is entering 2018 with a sharp focus on advancing our proprietary pipeline of novel anti-epileptic drugs, including XEN1101, a next-generation Kv7 potassium channel opener, and XEN901, a Nav1.6 sodium channel inhibitor, to treat both adult and orphan pediatric forms of severe epilepsy, such as EIEE7 and EIEE13. Looking ahead to key clinical data points, we expect to have the ongoing XEN1101 Phase 1 clinical trial completed by mid-year, including a pharmacodynamic read-out from the Phase 1b transcranial magnetic stimulation study. In the second half of this year, we anticipate having completed the XEN901 Phase 1 clinical trial. We anticipate that both XEN1101 and XEN901 could be in Phase 2 development by the end of this year. In addition, we will work towards expanding our pipeline of novel ion channel modulators through both our internal research efforts and our ongoing assessment of promising external product opportunities."